A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.

MLA

Dasyam, Nathaniel, et al. “A Randomised Controlled Trial of Long NY-ESO-1 Peptide-Pulsed Autologous Dendritic Cells with or without Alpha-Galactosylceramide in High-Risk Melanoma.” Cancer Immunology, Immunotherapy : CII, vol. 72, no. 7, July 2023, pp. 2267–82. EBSCOhost, https://doi.org/10.1007/s00262-023-03400-y.

APA

Dasyam, N., Sharples, K. J., Barrow, C., Huang, Y., Bauer, E., Mester, B., Wood, C. E., Authier-Hall, A., Dzhelali, M., Ostapowicz, T., Kumar, R., Lowe, J., Maxwell, A., Burn, O. K., Williams, G. M., Carley, S. E., Caygill, G., Jones, J., Chan, S. T. S., … Hermans, I. F. (2023). A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma. Cancer Immunology, Immunotherapy : CII, 72(7), 2267–2282. https://doi.org/10.1007/s00262-023-03400-y

Chicago

Dasyam, Nathaniel, Katrina J Sharples, Catherine Barrow, Ying Huang, Evelyn Bauer, Brigitta Mester, Catherine E Wood, et al. 2023. “A Randomised Controlled Trial of Long NY-ESO-1 Peptide-Pulsed Autologous Dendritic Cells with or without Alpha-Galactosylceramide in High-Risk Melanoma.” Cancer Immunology, Immunotherapy : CII 72 (7): 2267–82. doi:10.1007/s00262-023-03400-y.